Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Raymond Anderson Sells 3,142 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $68.35, for a total value of $214,755.70. Following the completion of the transaction, the director directly owned 5,373 shares of the company’s stock, valued at $367,244.55. This trade represents a 36.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Anderson also recently made the following trade(s):

• On Tuesday, August 25th, Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34.

Monopar Therapeutics Price Performance

MNPR stock opened at $67.22 on Friday. Monopar Therapeutics Inc. has a twelve month low of $50.07 and a twelve month high of $124.82. The company’s 50 day moving average is $87.73 and its two-hundred day moving average is $77.39.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, equities research analysts expect that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of large investors have recently bought and sold shares of MNPR. Bank of New York Mellon Corp purchased a new position in shares of Monopar Therapeutics during the second quarter worth about $7,124,000. Walleye Capital LLC purchased a new stake in Monopar Therapeutics during the 1st quarter valued at approximately $3,458,000. Siren L.L.C. raised its stake in Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after acquiring an additional 57,820 shares during the last quarter. Bank of America Corp DE lifted its position in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after acquiring an additional 53,336 shares during the period. Finally, ADAR1 Capital Management LLC lifted its position in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on MNPR. UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Morgan Stanley reissued an “overweight” rating and issued a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Zacks Research downgraded Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Finally, HC Wainwright raised their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.00.

Key Stories Impacting Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Neutral Sentiment: Monopar was projected to announce quarterly earnings on Thursday. The article did not provide results or specific expectations, leaving investors to look for updates in the report. Monopar earnings announcement preview
• Neutral Sentiment: A separate article about investment firms’ views on MNPR supplied no details on ratings, price targets, or recent positioning. Investment firms’ views on MNPR
• Negative Sentiment: Directors Kim Tsuchimoto and Raymond Anderson reported share sales. Tsuchimoto sold 2,891 shares on Nov. 4 and 1,199 on Nov. 2; Anderson sold 3,142 shares on Nov. 2. The sales reduced their holdings and could weigh on sentiment, though they were executed under pre-arranged Rule 10b5-1 plans. SEC filing on director share sales

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.